Johnson & Johnson (J&J) is in discussions to amass Intra-Cellular Therapies, an organization specialising in central nervous system disorder treatments, as reported by Bloomberg.
The deal might be finalised as early as mid-January 2025, although the confidential talks may not necessarily lead to an agreement.
Other potential buyers may also have an interest.
Intra-Cellular’s market value has soared to $10bn after a 40% increase in share price within the 12 months to January.
The corporate is understood for its approaches to mental health and neurological disorders, with a significant depressive disorder drug currently in late-stage trials.
Its shares rose following a recent settlement with Sandoz over Caplyta, a bipolar depression medication.
Meanwhile, J&J’s market capitalisation reportedly stands at $342bn, following a 12% decline over the identical one-year period.
J&J has not commented on the potential acquisition, which can be the most important biotech transaction in greater than a yr, highlighting a resurgence in healthcare deals after a slump.
The potential acquisition comes as J&J seeks to bolster its portfolio following the spin-off of its consumer health division and the $13.1bn acquisition of Shockwave Medical, a heart device manufacturer.
The move is an element of J&J’s technique to sustain growth amid challenges akin to the upcoming lack of exclusivity for its psoriasis treatment, Stelara.
In May 2024, J&J expanded its biotech footprint with the $850m acquisition of Proteologix, which focuses on immune-mediated diseases, with additional milestone payments possible.
“Johnson & Johnson in talks to amass Intra-Cellular Therapies” was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.
The data on this site has been included in good faith for general informational purposes only. It will not be intended to amount to advice on which it is best to rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You should obtain skilled or specialist advice before taking, or refraining from, any motion on the premise of the content on our site.